The research, conducted at a single German center and published in CVIR Oncology, followed 13 consecutive patients who underwent percutaneous CT-guided cryoablation of histologically confirmed desmoid tumors between January 2019 and December 2024. Most were young women with tumors embedded in the rectus abdominis muscle of the abdominal wall, the classic setting for this rare disease, which strikes roughly two to four people per million each year. Twelve of the thirteen had already failed at least one line of systemic therapy, ranging from nonsteroidal anti-inflammatory drugs and hormonal agents to chemotherapy and, in one case, a gamma-secretase inhibitor.

Cryoablation destroys tissue by cycling it between extreme cold and thaw. In this study, interventional radiologists placed between 2 and 16 thin cryoprobes directly into each tumor under CT fluoroscopic guidance while the patient was under general anesthesia. A standardized double freeze-thaw protocol followed: two ten-minute freeze cycles separated by passive and active thawing phases. During each freeze, the growing ice ball is visible on CT as a sharply defined dark region, a unique advantage of cryoablation over heat-based ablation techniques, allowing operators to watch the lethal zone expand in real time and confirm it covers the tumor with at least a five-millimeter margin.

The critical technical challenge lies in what surrounds these tumors. Because most desmoids in this cohort sat in the abdominal wall, the bowel loops immediately behind the target were the structures most at risk of catastrophic freeze injury. The team deployed protective dissection techniques in 76.9 percent of procedures: hydrodissection with 5 percent dextrose solution in just over half the cases, CO₂ pneumodissection in two patients, and air dissection in one. In laparoscopically assisted cases, surgeons created capnoperitoneum and directly observed the ice ball from inside the peritoneal cavity, retracting probes by pre-planned distances between freeze cycles to sculpt an enlarged zone of destruction. Every patient’s skin was protected with injected fluid and a warm saline-filled glove.

What distinguishes this study from earlier cryoablation series is its measurement strategy. Rather than tracking overall tumor diameter with standard RECIST criteria, the investigators systematically quantified the enhancing tumor volume on contrast-enhanced MRI, using the ellipsoid formula to calculate viable, cellular tissue separately from the non-enhancing fibrotic residue that persists long after successful ablation. This distinction proved dramatic. At a median follow-up of 14.5 months, median viable tumor volume collapsed from 70.5 cubic centimeters to just 1.97 cubic centimeters, a 98.3 percent reduction with a large statistical effect size. Yet the median entire lesion volume remained 6.7 cubic centimeters, and in the most striking individual case a patient retained a 251-cubic-centimeter residual mass of which less than 2 percent was living tissue.

That discrepancy carries a direct clinical warning. Conventional size-based response criteria, which measure the whole lesion including dead fibrotic tissue, would classify many of these successfully treated patients as having only stable or partial disease, badly underestimating how thoroughly the tumor had been devitalized. Applying modified RECIST criteria, which evaluate only the enhancing component, the authors found six of twelve evaluable patients achieved complete response and six achieved partial response, for an objective response rate of 100 percent. No patient showed progression during follow-up.

Objective MRI signal analysis corroborated the volumetric findings. The T2 contrast-to-noise ratio, a quantitative measure of how brightly tumor tissue stands out from background noise on T2-weighted images, fell from a median of 146.9 at baseline to 19.5 at last follow-up, reflecting replacement of highly cellular tumor by avascular fibrosis and coagulative necrosis. T2 signal intensity relative to muscle also dropped significantly. These quantitative markers align with prior work showing that intermediate T2 signal combined with nodularity and enhancement predicts post-ablation growth, offering clinicians measurable indicators of durable local control.

Patients themselves reported substantial benefit: twelve of thirteen described improved symptoms. The safety record, however, was not flawless. One patient, notably the only one treated without any prior therapy, suffered a severe grade 3b complication after the protective dissection was discontinued at cryoprobe retrieval before the ice ball had fully thawed. The residual ice contacted adjacent bowel and skin, causing bowel wall necrosis, cutaneous frostbite, and an enterocutaneous fistula requiring surgical repair; the patient was lost to follow-up. The remaining twelve patients experienced no complications at all, and the overall 7.7 percent major complication rate sits within the 0 to 17 percent range reported across published desmoid cryoablation series.

The results compare favorably with landmark studies. The prospective CRYODESMO-01 trial reported an 86 percent nonprogression rate at twelve months and a 79 percent objective response rate, while a ten-year pediatric and young adult series documented symptom improvement in 90 percent of patients but tumor volume reductions exceeding 75 percent in only 43 percent. The authors caution that their exceptional figures likely reflect selection bias and the small sample size, and that a median follow-up of 14.5 months cannot capture recurrences appearing years later.

Nevertheless, the study delivers a clear message for the multidisciplinary management of desmoid tumors. Cryoablation, positioned as a second- or third-line option after systemic therapy fails, achieves near-complete elimination of viable tumor with meaningful symptom relief and objective, quantitative MRI evidence of tumor death. The practical implication for radiologists and oncologists alike is to differentiate viable from total lesion volume when interpreting post-ablation imaging: large areas of residual non-enhancing tissue should never be mistaken for treatment failure. Larger prospective trials with patient-reported outcomes and extended follow-up are now needed to cement enhancing volume-based assessment as the standard endpoint for this increasingly credible, minimally invasive treatment.

The biology underlying desmoid tumors helps explain why local destruction can be so effective despite the tumors’ infiltrative habits. Most sporadic cases harbor activating mutations in the CTNNB1 gene, which stabilizes beta-catenin and drives the Wnt signaling pathway that fuels fibroblast proliferation. A minority arise in patients with familial adenomatous polyposis, where germline APC mutations set the stage. Because these tumors rarely metastasize, controlling the local disease is essentially controlling the whole disease, which is why a technique that devitalizes the entire enhancing component can translate into durable clinical benefit.

The demographic pattern of the disease also deserves emphasis. Desmoid tumors show a striking predilection for young women, and pregnancy and the postpartum period are recognized risk factors, with estrogen thought to modulate tumor behavior in at least a subset of patients. This means many patients face decades of life ahead of them at diagnosis, making the avoidance of radical surgery with its high recurrence rates and functional morbidity particularly consequential. An abdominal wall tumor in a woman of childbearing age, for example, can compromise core strength, posture, and future pregnancies if treated with wide resection, whereas a percutaneous needle-based approach preserves the muscle envelope even if some fibrotic residue remains.

The shift toward active surveillance as a first step deserves further context. Longitudinal observational cohorts have shown that a substantial fraction of desmoid tumors, in some series approaching half, either regress spontaneously or remain stable without any intervention. This observation, formalized in consensus guidelines from the Desmoid Tumor Working Group, fundamentally changed the treatment algorithm: intervention, whether systemic therapy, radiation, surgery, or ablation, is now reserved for tumors that progress on surveillance or cause significant symptoms. The patients in the cryoablation study fit squarely into this modern paradigm, having been selected precisely because their disease demanded treatment after systemic options were exhausted or declined.

On the mechanistic side, cryoablation’s lethality depends on achieving sufficiently low temperatures throughout the target volume. Vascularized tissue dies reliably when cooled to roughly minus twenty to minus forty degrees Celsius, with ice crystal formation disrupting cell membranes, vascular stasis producing ischemia, and the slow thaw phase amplifying the injury. The double freeze-thaw protocol used here exploits this last phenomenon: the second cycle kills cells already sensitized by the first, and the freeze-thaw alternation damages the microvasculature more thoroughly than a single prolonged freeze. This is why the authors insisted on an ablation margin of at least five millimeters beyond the enhancing tumor boundary, since the lethal isotherm sits inside the visible edge of the ice ball.

The choice of 5 percent dextrose in water for hydrodissection is also deliberate rather than arbitrary. Isotonic saline conducts electrical current and would be hazardous with radiofrequency ablation, but for cryoablation the more relevant property is thermal: fluid placed between tumor and bowel acts as a physical and thermal buffer, pushing heat-rich structures out of the freeze zone. Dextrose solution also avoids the theoretical concern of saline’s higher thermal conductivity accelerating ice growth toward protected structures.

Finally, the emergence of gamma-secretase inhibitors, exemplified by nirogacestat’s regulatory approval based on randomized trial evidence, has added a systemic option that did not exist for most of the study period. How ablation and these targeted agents will be sequenced remains an open question, and head-to-head comparisons incorporating volumetric endpoints, patient-reported symptom scores, and cost-effectiveness analysis will be needed to define each therapy’s proper place in a disease whose natural history is as variable as its treatment options are expanding.

Subject of Research: Percutaneous CT-guided cryoablation of desmoid tumors with volumetric MRI outcome assessment

Article Title: Percutaneous CT-guided cryoablation of desmoid tumors: single-center experience with volumetric midterm outcome

Article References: Schaaf, M., Sattler, T., Spatz, J., Surwald, S., Schraut, J., & Jakobs, T. F. (2026). Percutaneous CT-guided cryoablation of desmoid tumors: single-center experience with volumetric midterm outcome. CVIR Oncology, 2(1), Article 22. https://doi.org/10.1007/s44343-026-00060-4

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00060-4

Keywords: desmoid tumor, cryoablation, aggressive fibromatosis, interventional radiology, CT-guided ablation, volumetric assessment, mRECIST, MRI, hydrodissection, soft tissue tumor, minimally invasive, local recurrence

Vestibular schwannomas in NF2 patients represent a distinct clinical challenge that has long baffled neurologists and oncologists alike. Unlike sporadic cases, NF2-related VSs often present as multiple tumors, which are characterized by aggressive growth and the risk of substantial neurological impairment. Traditional approaches involving microsurgical resection carry significant risks, and the debate over the optimal management strategy has persisted for decades. The analyzed data in this study bring clarity by quantitatively assessing SRS outcomes, an increasingly popular minimally invasive technique known for its precision and potential to preserve neurological functions.

The meta-analysis compiled evidence from nineteen robust studies totaling 960 individuals and 1310 documented tumors. This expansive cohort allowed for finely tuned statistical power to evaluate local tumor control (LC) rates, hearing preservation outcomes, and adverse event profiles associated with SRS. Remarkably, the pooled LC was reported at 83%, a figure that mandates consideration of this modality as a frontline treatment option, particularly in light of the nuanced biological behavior of NF2-associated VSs.

One of the most compelling aspects elucidated by the researchers is the correlation between certain patient and tumor factors with treatment success. The analysis demonstrated that older patients experienced significantly higher LC rates. This age-related difference may reflect variances in tumor biology or radiosensitivity that warrant further molecular investigation. Additionally, patients undergoing SRS without prior surgical resection demonstrated better LC outcomes, suggesting that pre-treatment tumor handling may influence radiosurgical efficacy.

Tumor size emerged as a crucial determinant of therapeutic benefit. Specifically, smaller tumor volumes were associated with enhanced LC, reinforcing the clinical axiom that early intervention yields superior control. This insight advocates for heightened surveillance protocols and earlier radiosurgical intervention to optimize patient outcomes. The ability of SRS to precisely target these lesions without significant collateral damage presents a compelling alternative to the morbidity risks inherent in surgical excision.

Beyond tumor control, preservation of neurological function remains paramount in managing NF2-associated VSs. The meta-analysis reported a median serviceable hearing preservation rate of 42% post-SRS, an encouraging result given the tumor’s location within the delicate structures governing auditory function. Though modest, this rate highlights the intricate balance between tumor eradication and quality-of-life considerations, elevating SRS as a viable option for patients prioritizing sensory preservation.

Facial and trigeminal nerve function, critical to patients’ daily comfort and well-being, were also examined. Notably, the rate of trigeminal nerve worsening was a low 2%, while facial nerve impairment occurred in only 5% of cases. These figures underscore the precision capability of SRS to minimize damage to adjacent neural structures despite the inherently challenging anatomical context of these tumors situated near the brainstem and cranial nerve complexes.

The study also addresses a key safety consideration in radiosurgery—radionecrosis (RN)—a feared but relatively rare complication. In what is perhaps a most reassuring finding, no patients developed radionecrosis following SRS in the collective data. This absence reinforces the therapeutic window of SRS, confirming its safety profile over a broad patient population and encouraging clinicians to embrace this treatment knowing the risk of devastating radiation-induced brain injury is minimal.

Robust sensitivity analyses further reinforce the strength of the study’s conclusions. By verifying that findings were consistent across different study populations and methodologies, the researchers established moderate to high robustness, diminishing concerns of spurious correlations or bias. Additionally, the absence of publication bias enhances confidence that the pooled evidence presents an accurate reflection of clinical realities.

Clinicians and patients alike face significant decision-making dilemmas in NF2 treatment, given the complexity and chronic nature of the disease. The results of this meta-analysis offer an evidence-based foundation supporting SRS as an effective, minimally invasive alternative or adjunct to surgery, particularly for small- to medium-sized tumors where the risk-benefit ratio favors preservation of function alongside tumor control.

From a mechanistic perspective, the favorable outcomes of SRS may be linked to advances in targeting technologies, such as gamma knife and LINAC systems, that deliver highly conformal doses with submillimeter accuracy. This precision mitigates collateral damage and exploits the radiosensitivity of schwannoma cells, causing tumor growth arrest or regression while sparing normal tissue. Through a concerted effort combining radiosurgical sophistication and patient-tailored protocols, neurological morbidity can be minimized without compromising oncologic efficacy.

Looking forward, the findings prompt important avenues for future research, including investigations into molecular predictors of radiosensitivity in NF2-associated schwannomas, refinement of dosimetric parameters, and integration of radiosurgery with systemic therapies. The heterogeneity in tumor behavior, particularly in younger patients and those with larger lesions, underscores the need for personalized therapeutic strategies guided by genomic and radiological biomarkers.

Moreover, longitudinal follow-up data beyond the immediate post-treatment phase will be crucial to understanding the durability of tumor control and the long-term preservation of hearing and nerve function. Given the chronic progression of NF2, studies tracking years to decades post-SRS will provide invaluable insights into late effects and secondary malignancy risks, enabling refined patient counseling and surveillance protocols.

This landmark meta-analysis signals a paradigm shift in how the medical community approaches vestibular schwannomas in neurofibromatosis type 2. By solidifying the role of stereotactic radiosurgery as an effective and safe treatment option, it empowers clinicians to navigate the trade-offs between tumor management and retention of neurological function with greater clarity. Ultimately, this will translate into improved patient quality of life and potentially enhanced survival outcomes in this complex disease setting.

Overall, the study embodies a critical synthesis of current evidence that will resonate through multidisciplinary neuro-oncology teams worldwide. It supports the transition from invasive surgical excision toward more refined, technology-driven modalities tailored to the unique challenges of NF2. In the rapidly evolving landscape of cancer therapeutics, such meta-analyses are indispensable in guiding clinical practice and shaping future scientific inquiry.

As researchers and clinicians continue to unravel the complexities of NF2-associated vestibular schwannomas, stereotactic radiosurgery stands out as a beacon of hope—one that combines precision, efficacy, and safety in the quest to transform lives affected by this daunting hereditary condition.

Subject of Research: Stereotactic radiosurgery outcomes for neurofibromatosis type 2-associated vestibular schwannomas

Article Title: Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2: a systematic review and meta-analysis

Article References:
Hajikarimloo, B., Tos, S.M., Alvani, M.S. et al. Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2: a systematic review and meta-analysis. BMC Cancer 25, 698 (2025). https://doi.org/10.1186/s12885-025-13959-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-13959-7